Author Archive

CPRX Phase 3 data due 3Q. Offerings for SGMO NBY + update for PTLA

Mar 20, 2014 No Comments

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it has commenced a $100 million underwritten public offering of shares of its common stock. NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) announced that it intends to offer shares of its common stock and warrants in an underwritten public offering. Portola Pharmaceuticals (Nasdaq:PTLA) announced that it has initiated a Phase 3 […]

Read more

AERI Phase 2b data due early 3Q + updates for ADHD and IRWD.

Mar 19, 2014 No Comments

Alcobra Ltd. (Nasdaq:ADHD) announced that the first patient has been enrolled in a Phase 3 clinical trial of MDX in the treatment of Adults with ADHD. The trial is expected to be completed in 2H 2014. Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced that dosing has begun in its Phase 2a trial of IW-3718 in patients suffering from […]

Read more

NKTR Adcom date set. ICPT meets Phase 3 POISE endpoint + GWPH INO updates

Mar 18, 2014 No Comments

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced that it met the primary endpoint in its international Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) demonstrated that OCA, at both a 10 mg dose and a 5 mg dose titrated to 10 mg. Nektar Therapeutic (NASDAQ: NKTR) and AstraZeneca have been […]

Read more

APPY pivotal data due Thursday. ITMN offering.

Mar 13, 2014 No Comments

Venaxis, Inc. (Nasdaq: APPY) announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test on Thursday, March 13, 2014, at 8:30 a.m. ET.  InterMune, Inc. (NASDAQ: ITMN) announced that it plans to offer 7,500,000 shares of its common stock in an underwritten public offering.

Read more

OXGN hits primary endpoint. SNTA data release extension +updates for SSH and OGXI

Mar 12, 2014 No Comments

OXiGENE, Inc. (Nasdaq:OXGN) announced that it met its primary endpoint of a statistically significant increase in progression-free survival in its Phase 2 clinical trial evaluating Avastin(bevacizumab) with or without ZYBRESTAT to treat patients with recurrent ovarian cancer. One of their secondary endpoints, objective response rate, was higher but not statistically significant. All patients will continue to be followed for […]

Read more

ETRM Adcom rescheduled.

Mar 11, 2014 No Comments

EnteroMedics Inc. (NASDAQ: ETRM) announced that the FDA has rescheduled the Advisory Committee meeting of the Center for Devices and Radiologic Health’s (CDRH) for Tuesday, June 17, 2014 to review the Maestro System delivering VBLOC vagal blocking therapy as a treatment for morbid obesity. The company noted that the delay is due to a scheduling conflict on behalf of the CDRH. […]

Read more

Pipeline updates for NBY NWBO CMRX ACHN NLNK

Mar 08, 2014 No Comments

NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) provided an update noting that data from their Viral Conjunctivitis Phase 2 trial are due in mid-2014. Northwest Biotherapeutics (NASDAQ: NWBO) announced the Data Safety Monitoring Board (DSMB) review of the efficacy data of their Phase 3 GBM Trial is still pending. Regarding the safety review, the DSMB have reviewed the […]

Read more

INSM data due late March. ENDP FDA Approval. FLML offering + updates for TTPH SNSS ADHD PTCT

Mar 07, 2014 No Comments

Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced the FDA approval of AVEED (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone. Flamel Technologies, S.A. (NASDAQ: FLML) announced that it is offering to sell American Depositary Shares (ADSs), […]

Read more

Pipeline updates for OPK CLDX ANAC CNAT ACRX GEVA. Offering news for ACAD BLRX

Mar 04, 2014 No Comments

Anacor Pharmaceuticals (NASDAQ:ANAC) announced that following an End-of-Phase 2 meeting with the FDA, a Phase 3 trial of AN2728 for the topical treatment of mild-to-moderate atopic dermatitis is scheduled to commence by the start of May 2014. Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced the initiation of a Phase 2 clinical trial of emricasan, in patients with nonalcoholic […]

Read more

NKTR Phase 3 data due early 2015.Offerings for INO SNSS + XLRN update

Feb 27, 2014 No Comments

Nektar Therapeutics (Nasdaq: NKTR) provided a pipeline update noting that topline data from the Phase 3 pivotal trial of NKTR-102 in advanced breast cancer are due in early 2015. Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its […]

Read more

BCRX PDUFA date set. ITMN Phase 3 IPF trial meets endpoints. NBIX offering + ANIK approval.

Feb 26, 2014 No Comments

BioCryst Pharmaceuticals, Inc.(Nasdaq:BCRX) announced that the FDA has accepted for review the New Drug Application (NDA) for intravenous (i.v.) peramivir, with a PDUFA date of December 23, 2014. No Advisory Committee review is planned at this stage. Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public […]

Read more